Feb 4 2010
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
presentation of preclinical data on a series of novel compounds that
simultaneously blocked two critical pathways involved in the growth and
survival of cancer cells. The compounds were identified as part of the
Company’s ongoing oncology drug discovery efforts. The data are being
presented in both oral and poster sessions at the American Association
for Cancer Research (AACR) conference on Protein Translation and Cancer
in Coronado, CA.
“Progenics’ identification of these small-molecule compounds as part of
our discovery program underscores our long-standing commitment to
oncology drug development”
“Progenics’ identification of these small-molecule compounds as part of
our discovery program underscores our long-standing commitment to
oncology drug development,” stated Paul J. Maddon, M.D., Ph.D., Founder,
Chief Executive Officer and Chief Science Officer of Progenics. “In
laboratory studies, the synthetic, small-molecule compounds blocked both
phosphoinositide 3-kinase (PI3K), which is a key regulator of one
molecular signaling pathway, and MNK, an oncogenic kinase in the Ras
pathway. We look forward to exploring the therapeutic potential of this
series of compounds which are being optimized for clinical development.”
“Our findings add to a growing body of scientific evidence that
demonstrates the importance of blocking both the PI3K and Ras pathways
at once,” said William C. Olson, Ph.D., Senior Vice President, Research
and Development at Progenics. “These interlinked cellular pathways are
directly involved in a variety of difficult-to-treat cancers. The cancer
cells become dependent on each of these pathways, such that when one
pathway is blocked, the cells often adjust to use the other pathway.
Blocking both pathways simultaneously can switch off oncogenic signaling
altogether and therefore holds great promise as a strategy to combat
some of our most aggressive forms of cancer.”
Multiplex PI3K inhibitors: Summary of results
The multiplex PI3K inhibitors discovered by Progenics constitute a novel
series of synthetic, drug-like compounds that, in vitro,
demonstrated potent activity against diverse tumor cells, including
those derived from lung, colon, liver, breast, prostate and pancreatic
cancers. Activity was demonstrated against both PI3K and MNK, an
oncogenic kinase in the Ras pathway. Kinases are enzymes that modify
other molecules by chemically adding phosphate groups to them
(phosphorylation). Phosphorylation frequently results in a change in the
biological activity of molecules. In in vitro assays, the
multiplex PI3K inhibitor compounds exhibited potent cell-eradicating
activity against cancer cells containing activating mutations in either
or both the PI3K and Ras pathways. In addition to blocking PI3K- and
Ras-dependent signaling in cells, the compounds selectively blocked
expression of critical growth and survival proteins that are associated
with cancer, without altering the expression of “housekeeping” proteins
that are associated with normal cellular functions.
The presentation, entitled, “Novel Multiplex PI3-Kinase Inhibitors
Potently Inhibit Ras-mutated Tumors via Suppression of eIF-4E-mediated
Protein Translation” is scheduled for presentation in a plenary session
at the AACR Conference on Protein Translation and Cancer on Saturday,
February 6th by Mark Hamilton, Ph.D., Investigator, Drug Discovery at
Progenics. These data are also being presented at the Conference in a
poster session today. A copy of the poster can be accessed via the
following link:
SOURCE Progenics Pharmaceuticals, Inc.